Cystotic levels of an estrogen-induced breast cancer-associated peptide (TFF1/pS2) in colorectal cancer: Clinical significance and relationship with steroid receptors

International Journal of Biological Markers

Volumn 18, Issue 4, 2003, Pages 301-310

  Vizoso, F J ^a,b   Fagilde, M C ^c   Corte, M D ^b   Corte, M G ^b   Gava, R ^b   Bongera, M ^a   Allende, M T ^c   Garcia Muniz J L ^c  

^a HOSPITAL DE JOVE   (Spain)

^b Principado de Asturias   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Colorectal cancer; Estrogen receptors; Progesterone receptors; Prognosis; Trefoil peptides

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; INTESTINAL TREFOIL FACTOR; LEVAMISOLE; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN PS2; STEROID RECEPTOR; PROTEIN; TFF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CELL CYCLE S PHASE; CELLULAR DISTRIBUTION; COLORECTAL CANCER; CONTROLLED STUDY; DESCENDING COLON; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PLOIDY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECTUM TUMOR; TUMOR LOCALIZATION; ADOLESCENT; BREAST TUMOR; CHILD; COLON TUMOR; COLORECTAL TUMOR; CYTOSOL; DISEASE FREE SURVIVAL; GENETICS; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; SURVIVAL; TIME;

LOTUS; MINK CELL FOCUS-FORMING VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHILD; CHILD, PRESCHOOL; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; CYTOSOL; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; INTESTINAL MUCOSA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECTAL NEOPLASMS; RNA, MESSENGER; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 1242274574     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.4287     Document Type: Article

References (70)

1. Thim L. Trefoil peptides: from structure to function. Cell Mol Life Sci 1997; 53: 888-903.
2. Ribieras S, Tomasetto C, Rio MC. The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim Biophys Acta 1998; 1378: F61-77.
3. Wong WM, Poulsom R, Wright NA. Trefoil peptides. Gut 1999; 44: 890-5.
4. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 1982; 10: 7895-903.
5. Rio MC, Bellocq JP, Daniel JY, et al. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science 1988; 241: 705-8.
6. Luqmani Y, Bennett C, Paterson I, et al. Expression of the pS2 gene in normal, benign and neoplastic human stomach. Int J Cancer 1989; 44: 806-12.
7. Theisinger B, Welter C, Grzeschik KH, Blin N. Assignment of the gene for human spasmolytic protein (hSP/SML1) to chromosome 21. Hum Genet 1992; 89: 681-2.
8. Muller W, Borchard F. pS2 protein in gastric carcinoma and normal gastric mucosa: association with clincopathological parameters and patient survival. J Pathol 1993; 171: 263-9.
9. Hanby AM, Poulsom R, Elia G, Singh S, Longcroft JM, Wright NA. The expression of the trefoil peptides pS2 and human spasmolytic polypeptide (hSP) in 'gastric metaplasia' of the proximal duodenum: implications for the nature of 'gastric metaplasia'. J Pathol 1993; 169: 355-60.
10. Pallud C, Le Doussal V, Pichon MF, Prud'homme JF, Hacene K, Milgrom E. Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumours. Histopathology 1993; 23: 249-56.
11. Hahnel E, Robbins P, Hahnel R. Expression of the pS2 gene in normal breast tissue. Breast Cancer Res Treat 1993; 28: 295-7.
12. Jakowlew SB, Breathnach R, Jeltsch JM, Masiakowski P, Chambon P. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res 1984; 12: 2861-78.
13. Rio MC, Chambon P. The pS2 gene, mRNA, and protein: a potential marker for human breast cancer. Cancer Cells 1990; 2: 269-74.
14. Thompson AM, Hawkins RA, Elton RA, Steel CM, Chetty U, Carter DC. pS2 is an independent factor of good prognosis in primary breast cancer. Br J Cancer 1993; 68: 93-6.
15. Spyratos F, Andrieu C, Hacene K, Chambon P, Rio MC. pS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer 1994; 69: 394-7.
16. Soubeyran I, Quenel N, Coindre JM, et al. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer 1996; 74: 1120-5.
17. Higashiyama M, Doi O, Kodama K, et al. Prognostic significance of pS2 protein expression in pulmonary adenocarcinoma. Eur J Cancer 1994; 6: 792-7.
18. Higashiyama M, Doi O, Kodama K, Yokuchi H, Inaji H, Tateishi R. Estimation of serum level of pS2 protein in patients with lung adenocarcinoma. Anticancer Res 1996; 16: 2351-5.
19. Welter C, Theisinger B, Seitz G, et al. Association of the human spasmolytic polypeptide and an estrogen-induced breast cancer protein (pS2) with human pancreatic carcinoma. Lab Invest 1992; 66: 187-92.
20. Collier JD, Bennett MK, Bassendine MF, Lendrum R. Immunolocalization of pS2, a putative growth factor, in pancreatic carcinoma. J Gastroenterol Hepatol 1995; 10: 396-400.
21. Bonkhoff H, Stein U, Welter C, Remberger K. Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum Pathol 1995; 26: 824-8.
22. Lipponen PK, Eskelinen MJ. Expression of pS2 protein in transitional cell bladder tumours. J Pathol 1994; 173: 327-32.
23. Wang DG, Liu WH, Lundy FT, et al. TFF1 gene expression in human medullary thyroid carcinoma. J Pathol 1998; 184: 408-13.
24. Hanby AM, McKee P, Jeffery M, et al. Primary mucinous carcinomas of the skin express TFF1, TFF3, estrogen receptor, and progesterone receptors. Am J Surg Pathol 1998; 22: 1125-31.
25. Wysocki SJ, Hahnel E, Masters A, Smith V, McCartney AJ, Hahnel R. Detection of pS2 messenger RNA in gynecological cancers. Cancer Res 1990; 50: 1800-2.
26. Singh S, Poulsom R, Wright NA, Sheppard MC, Langman MJ. Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer. Gut 1997; 40: 516-20.
27. Suarez C, Vizoso F, Rodriguez JC, et al. Prognostic significance of cytosolic pS2 protein content in gastric cancer. Int J Biol Markers 2001; 16: 37-44.
28. Williams R, Stamp GW, Gilbert C, Pignatelli M, Lalani EN. pS2 transfection of murine adenocarcinoma cell line 410.4 enhances dispersed growth pattern in a 3-D collagen gel. J Cell Sci 1996; 109: 63-71.
29. Bossenmeyer-Pourie C, Kannan R, Ribieras S, et al. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol 2002; 157: 761-70.
30. Shousha S, Luqmani YA, Sannino P, Rio MC, Coombes RC, Theodorou NA. pS2 immunostaining of colorectal carcinoma. Mod Pathol 1993; 6: 446-8.
31. Hackel C, Falkenberg B, Gunther T, Lippert H, Roessner A. The pS2 protein in colorectal carcinomas and metastases. Pathol Res Pract 1998; 194: 171-6.
32. Welter C, Theisinger B, Rio MC, Seitz G, Schuder G, Blin N. Expression pattern of breast-cancer-associated protein pS2/BCEI in colorectal tumors. Int J Cancer 1994; 56: 52-5.
33. Junco A, Rodriguez JC, Allende MT, Garcia-Muniz JL, Gonzalez JJ, Vizoso F. The pS2 protein in primary colorectal carcinomas and in surrounding mucosa. Int J Biol Markers 1999; 14: 189-91.
34. Herrmann JB. Breast cancer and associated extramammary malignant neoplasms. Am J Surg 1972; 124: 620-4.
35. Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. Epidemiol Rev 1993; 15: 499-545.
36. Wingo PA, Ries LA, Parker SL, Heath CW Jr. Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev 1998; 7: 271-82.
37. Hebert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev 1998; 7: 653-9.
38. Meggouh F, Lointier P, Saez S. Sex steroid and 1,25-dihydroxyvitamin D3 receptors in human colorectal adenocarcinoma and normal mucosa. Cancer Res 1991; 51: 1227-33.
39. Singh S, Sheppard MC, Langman MJ. Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors. Gut 1993; 34: 611-5.
40. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 2000; 60: 245-8.
41. Raigoso P, Sanz L, Vizoso F, et al. Estrogen and progesterone receptors in colorectal cancer and surrounding mucosa. Int J Biol Markers 2001; 16: 262-7.
42. Cavallini A, Messa C, Pricci M, Caruso ML, Barone M, Di Leo A. Distribution of estrogen receptor subtypes, expression of their variant forms, and clinicopathological characteristics of human colorectal cancer. Dig Dis Sci 2002; 47: 2720-8.
43. Hermaneck P, Sobin L. UICC TNM classification of malignant tumors, 4th ed. Berlin: Springer Verlag, 1992.
44. Dukes C. The classification of cancer of the rectum. J Pathol Bacteriol 1932; 35: 323-32.
45. Broders A. The grading of carcinoma. Minn Med 1925; 8: 726-30.
46. Hedley DW, Shankey TV, Wheeless LL. DNA cytometry consensus conference. Cytometry 1993; 14: 471.
47. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
48. Raigoso P, Junco A, Andicoechea A, et al. Tissue-type plasminogen activator (tPA) content in colorectal cancer and in surrounding mucosa: relationship with clinicopathologic parameters and prognostic significance. Int J Biol Markers 2000; 15: 44-50.
49. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
50. Mantel N, Myers M. Problems of convergence of maximun likehood iterative procedures in multiparameter situations. J Am Stat Assoc 1971; 66: 484-91.
51. Rio MC, Chenard MP, Wolf C, et al. Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract. Gastroenterology 1991; 100: 375-9.
52. Wright NA, Poulsom R, Stamp G, et al. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology 1993; 104: 12-20.
53. Tomasetto C, Wolf C, Rio MC, et al. Breast cancer protein PS2 synthesis in mammary gland of transgenic mice and secretion into milk. Mol Endocrinol 1989; 3: 1579-84.
54. Singh S, Poulsom R, Hanby AM, et al. Expression of oestrogen receptor and oestrogen-inducible genes pS2 and ERD5 in large bowel mucosa and cancer. J Pathol 1998; 184: 153-60.
55. Henry JA, Bennett MK, Piggott NH, Levett DL, May FE, Westley BR. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer 1991; 64: 677-82.
56. Poulsom R, Hanby AM, Lalani EN, Hauser F, Hoffmann W, Stamp GW. Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol 1997; 183: 30-8.
57. Gillesby BE, Zacharewski TR. pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers. Breast Cancer Res Treat 1999; 56: 253-65.
58. Nogueira AM, Machado JC, Carneiro F, Reis CA, Gott P, Sobrinho-Simoes M. Patterns of expression of trefoil peptides and mucins in gastric polyps with and without malignant transformation. J Pathol 1999; 187: 541-8.
59. Thompson AM, Elton RA, Hawkins RA, Chetty U, Steel CM. PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer. Br J Cancer 1998; 77: 492-6.
60. dos Santos Silva E, Ulrich M, Doring G, Botzenhart K, Gott P. Trefoil factor family domain peptides in the human respiratory tract. J Pathol 2000; 190: 133-42.
61. Brown AM, Jeltsch JM, Roberts M, Chambon P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci U S A 1984; 81: 6344-8.
62. Baldwin WS, Travlos GS, Risinger JI, Barrett JC. Melatonin does not inhibit estradiol-stimulated proliferation in MCF-7 and BG-1 cells. Carcinogenesis 1998; 19: 1895-900.
63. Berry M, Nunez AM, Chambon P. Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci U S A 1989; 86: 1218-22.
64. Sonnenschein C, Szelei J, Nye TL, Soto AM. Control of cell proliferation of human breast MCF7 cells; serum and estrogen resistant variants. Oncol Res 1994; 6: 373-81.
65. Badia E, Duchesne MJ, Semlali A, et al. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res 2000; 60: 4130-8.
66. Martin V, Ribieras S, Song-Wang XG, et al. Involvement of DNA methylation in the control of the expression of an estrogen-induced breast-cancer-associated protein (pS2) in human breast cancers. J Cell Biochem 1997; 65: 95-106.
67. Emami S, Le Floch N, Bruyneel E, et al. Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. Faseb J 2001; 15: 351-61.
68. Prest SJ, May FE, Westley BR. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. Faseb J 2002; 16: 592-4.
69. Lefebvre O, Chenard MP, Masson R, et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996; 274: 259-62.
70. Calnan DP, Westley BR, May FE, Floyd DN, Marchbank T, Playford RJ. The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. J Pathol 1999; 188: 312-7.